Noninvasive Diagnosis and Evaluation of Curative Surgery for Gastric Cancer by Using NMR-based Metabolomic Profiling

Jung, Jeeyoun; Jung, Youngae; Bang, Eun Jung; Cho, Sung-Il; Jang, Young-Joo; Kwak, Jungwon; Ryu, Do Hyun; Park, Sung Soo; Hwang, Gwi Seo

doi:10.1245/s10434-014-3886-0

Cited by 88 publications

(102 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies reported that caffeine inhibited colon cancer cell proliferation and reduced colorectal cancer risk 17,18 . Decreased hypoxanthine level was detected in the urine of patients with Non-Hodgkin lymphoma 19 , and the same trend of reduced level was observed in gastric cancer patients compared to normal individuals 20 . Hypoxanthine level showed reduction in the serum of advanced rectal cancer patients when it was compared between different stages of tumor progression 21 , which is consistent with our findings.…”

Section: Discussionsupporting

confidence: 55%

Global and targeted serum metabolic profiling of colorectal cancer progression

Yin

Sánchez-Espiridión

Lin

et al. 2017

Cancer

View full text Add to dashboard Cite

Background Patients with colorectal adenoma polyps (PLP) are at higher risk of developing colorectal cancer (CRC). However, the development of improved and robust biomarkers to enable screening, surveillance and early detection of PLP and CRC continues to be a challenge. The aim of this study was to identify biomarkers of progression to CRC by metabolomic profiling of human serum samples using a multistage approach. Methods Metabolomic profiling was conducted using Metabolon platform for 30 PLP, 30 CRC and 30 control subjects followed by targeted validation of top metabolites in an additional set of 50 CRC, 50 PLP and 50 controls using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Unconditional multivariable logistic regression models adjusted for covariates were used to evaluate association with PLP and CRC risks. Results For the discovery phase, 404 serum metabolites were detected with 50 metabolites showing differential levels between PLP, CRC and controls (P for trend<0.05). Following validation, three top metabolites (xanthine, hypoxanthine and D-mannose) were validated showing lower levels of xanthine and hypoxanthine and higher level of D-mannose in PLP and CRC cases compared to controls. Further exploratory analysis of metabolic pathways revealed key roles for urea cycle and caffeine metabolism associated with PLP and CRC risks. Additionally, joint effect of top metabolites with smoking and significant interaction with BMI were also observed. Analysis of hypoxanthine to xanthine levels as ratio indicated association with CRC progression. Conclusions Our results suggest the potential utility of circulating metabolites as novel biomarkers for early detection of CRC.

show abstract

Section: Discussionsupporting

confidence: 55%

Global and targeted serum metabolic profiling of colorectal cancer progression

Yin

Sánchez-Espiridión

Lin

et al. 2017

Cancer

View full text Add to dashboard Cite

show abstract

“…4-hydroxyphenylacetate, alanine, phenylacetylglycine, mannitol, glycolate, and arginine levels were significantly correlated with cancer T stage. Together with hypoxanthine level, the above mentioned metabolites were tended toward control after surgical treatment [32] . In a study by Chen et al [33] , urinary lactic acid, arginine, leucine, isoleucine and valine were significantly higher, while citric acid, histidine, methionine, serine, aspartate, malic acid, and succinate were remarkably lower in the gastric cancer patients vs controls.…”

Section: Urinary Metabolomics In Gi Cancersmentioning

confidence: 98%

“…In addition, the urinary valine and isoleucine levels were lower in advanced stages compared to early-stages of cancer [33] . Another study also showed that urinary metabolomics could effectively differentiate gastric cancer patients from controls [34] ; however, the metabolites which were distinctive, were different than previously mentioned studies [32,33] , suggesting complexity in interpreting metabolomics results.…”

Section: Urinary Metabolomics In Gi Cancersmentioning

confidence: 99%

Urinary metabolites as noninvasive biomarkers of gastrointestinal diseases: A clinical review

Sarosiek¹,

Schicho²,

Blandon³

et al. 2016

WJGO

View full text Add to dashboard Cite

The diagnosis of gastrointestinal (GI) disorders is usually based on invasive techniques such as endoscopy. A key important factor in GI cancer is early diagnosis which warrants development of non-or lessinvasive diagnostic techniques. In addition, monitoring and surveillance are other important parts in the management of GI diseases. Metabolomics studies with nuclear magnetic resonance and mass spectrometry can measure the concentration of more than 3000 chemical compounds in the urine providing possible chemical signature in different diseases and during health. In this review, we discuss the urinary metabolomics signature of different GI diseases including GI cancer and elaborate on how these biomarkers could be used for the classification, early diagnosis and the monitoring of the patients. Moreover, we discuss future directions of this still evolving field of research. Core tip: Scientists are always searching for new disease biomarkers. An acceptable biomarker could help us in early diagnosis and classification of the diseases as well as the prediction of disease outcome. The diagnosis of gastrointestinal (GI) diseases is usually based on techniques such as upper or lower GI endoscopy, while highly sensitive and specific non-invasive diagnostic or screening tools are usually lacking. In this review, we have discussed the potentials of urinary metabolomics study as a future tool for the screening, diagnosis, classification and surveillance of GI diseases including inflammatory bowel disease and cancer.

show abstract

“…NMR analytics have been used for biomarker detection in humans in several tumor entities other than PCa (Table 2): non-small-cell lung cancer (Doskocz et al, 2015), oral squamous cell carcinoma (OSCC) , gastric cancer (Jung et al, 2014), myeloma (Lodi et al, 2013), pancreatic ductal adenocarcinoma (Davis et al, 2013), lung cancer (Carrola et al, 2011), and BCa (Bansal et al, 2013).…”

Section: Prostate Cancermentioning

confidence: 99%

Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer

Yang

Lü

Wen

et al. 2017

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Prostate cancer (PCa) is the second most common male cancer worldwide and the fifth leading cause of death from cancer in men. Early detection and risk stratification is the most effective way to improve the survival of PCa patients. Current PCa biomarkers lack sufficient sensitivity and specificity to cancer. Metabolite biomarkers are evolving as a new diagnostic tool. This review is aimed to evaluate the potential of metabolite biomarkers for early detection, risk assessment, and monitoring of PCa. Of the 154 identified publications, 27 and 38 were original papers on urine and serum metabolomics, respectively. Nuclear magnetic resonance (NMR) is a promising method for measuring concentrations of metabolites in complex samples with good reproducibility, high sensitivity, and simple sample processing. Especially urine-based NMR metabolomics has the potential to be a cost-efficient method for the early detection of PCa, risk stratification, and monitoring treatment efficacy.

show abstract

Noninvasive Diagnosis and Evaluation of Curative Surgery for Gastric Cancer by Using NMR-based Metabolomic Profiling

Abstract: An urinary metabolomics approach may be useful for the effective diagnosis of GC.

Cited by 88 publications

References 37 publications

Global and targeted serum metabolic profiling of colorectal cancer progression

Global and targeted serum metabolic profiling of colorectal cancer progression

Urinary metabolites as noninvasive biomarkers of gastrointestinal diseases: A clinical review

Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer

Contact Info

Product

Resources

About